Well Referenced

Category: Weight Management & Obesity

Medical and nutritional strategies for sustainable weight control

Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists

This 2021 review by Ard et al. examines the mechanisms, clinical efficacy, and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in obesity management. GLP-1RAs, initially developed for type 2 diabetes, promote weight loss by enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite through central nervous system pathways.

Read More »
June 26, 2025 No Comments

Semaglutide as a Promising Antiobesity Drug

This review article discusses the potential of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), as an effective treatment for obesity. Semaglutide’s long elimination half-life allows for once-weekly subcutaneous administration. It has been approved by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for

Read More »
June 26, 2025 No Comments

What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review

This systematic review and economic evaluation, published in 2012, assessed the clinical and cost-effectiveness of pharmacological interventions for obesity management in primary care settings. The study analyzed data from randomized controlled trials focusing on orlistat, sibutramine, and rimonabant. All three medications demonstrated modest weight loss benefits compared to placebo, with

Read More »
June 26, 2025 No Comments

Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an East Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial

This phase 3a randomized, double-blind, double-dummy, placebo-controlled trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg in East Asian adults with overweight or obesity, with or without type 2 diabetes. Participants were randomized to receive semaglutide or placebo for 68 weeks, alongside lifestyle interventions. The primary endpoint

Read More »
June 26, 2025 No Comments

Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials

This systematic review and network meta-analysis evaluated the comparative efficacy and safety of subcutaneously administered tirzepatide versus semaglutide in adults with type 2 diabetes. The analysis included data from multiple randomized controlled trials, assessing outcomes such as glycemic control (HbA1c reduction), weight loss, and adverse events. Results indicated that tirzepatide

Read More »
June 26, 2025 No Comments

Review of Head-to-Head Comparisons of Glucagon-Like Peptide-1 Receptor Agonists

This comprehensive review by Sten Madsbad, published in Diabetes, Obesity & Metabolism, analyzes nine phase III and one large phase II head-to-head trials comparing six GLP-1 receptor agonists (GLP-1RAs) for type 2 diabetes management. The agents are categorized into short-acting (exenatide twice daily, lixisenatide once daily) and long-acting (liraglutide once

Read More »
June 26, 2025 No Comments

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect

This 2021 review by Fisman and Tenenbaum discusses tirzepatide, a dual GIP and GLP-1 receptor agonist, as an innovative treatment for type 2 diabetes and obesity. Clinical trials, notably the SURPASS program, have demonstrated that tirzepatide significantly reduces HbA1c levels and body weight in a dose-dependent manner, outperforming existing therapies

Read More »
June 26, 2025 No Comments

Safety of Semaglutide

This comprehensive review evaluates the safety profile of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) approved for both subcutaneous and oral administration in managing type 2 diabetes and obesity. Clinical trials, including the SUSTAIN and PIONEER programs, have demonstrated semaglutide’s efficacy in glycemic control and weight reduction. Common adverse events

Read More »
June 26, 2025 No Comments